Tumor Resectability and Pathologic Response After Neoadjuvant Long-Course Chemoradiotherapy for Locally Advanced Rectal Cancer in a Resource-Limited Setting
Halake, S. S.; Bedada, H. F.; Desalegn, T. M.; Feyisa, T. B.; Tsige, K. A.; Woldetsadik, E. S.; Kantelhardt, E. J.
Show abstract
Purpose In resource-limited settings, locally advanced rectal cancer (LARC) often presents at advanced stages. Long-course chemoradiotherapy (LCCRT) remains a cornerstone of neoadjuvant therapy, yet outcome data from such settings remain limited. This study assessed tumor resectability, pathologic response, and factors associated with resectability following neoadjuvant LCCRT at Ethiopias largest tertiary oncology center. Methods A retrospective cohort study was conducted among patients with stage II-III rectal adenocarcinoma (cT3-4 and/or cN+) who completed neoadjuvant LCCRT at Tikur Anbessa Specialized Hospital between 2018 and 2023. Tumor resectability was determined by multidisciplinary team (MDT) assessment. Multivariable logistic regression was used to identify factors associated with post-LCCRT resectability, adjusting for initial T stage, circumferential resection margin (CRM) status, histologic subtype, radiotherapy technique, and neoadjuvant regimen. Results Among 58 eligible patients (median age 45 years; 62% male), 62% had cT4 tumors, 53% had cN2 disease, and 84.5% had involved CRM. The median diagnosis-to-LCCRT interval was 64 weeks (interquartile range [IQR], 37-82). After LCCRT, 27 patients (46.6%) were deemed resectable by MDT assessment; 19 patients (32.8%) ultimately underwent curative-intent surgery (median interval from LCCRT to surgery, 10 weeks; IQR, 7-15). Initial cT3 stage was associated with higher odds of resectability (adjusted odds ratio [AOR], 6.2; 95% CI, 1.06-36.37), whereas receipt of total neoadjuvant therapy was associated with lower odds (AOR, 0.10; 95% CI, 0.02-0.49). No pathologic complete responses were observed. Conclusion In this cohort characterized by advanced disease at presentation and treatment delays, neoadjuvant LCCRT resulted in low resectability and limited pathologic response. To enhance curative potential, concerted efforts are needed to expedite the timely initiation of radiotherapy, optimize multidisciplinary team assessment, and increase surgical capacity.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Tissue Factor Expression in Penile Squamous Cell Carcinoma: A Marker of HPV-Independent Disease 94%
- Molecular Heterogeneity in Early-Onset Colorectal Cancer: Pathway-Specific Insights in High-Risk Populations 94%
- Ethnicity-Specific Molecular Alterations in MAPK and JAK/STAT Pathways in Early-Onset Colorectal Cancer 93%
Similar papers in this journal
- Study Protocol of A Phase II Study to Evaluate Safety and Efficacy of Neo-adjuvant Pembrolizumab and Radiotherapy in Localized Rectal Cancer 94%
- Feasibility of Administering Human Pancreatic Cancer Chemotherapy in a Spontaneous Pancreatic Cancer Mouse Model 94%
- ALLIANCE A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer 94%
Similar papers in this journal
- Survival benefits of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma: evidence from a SEER-based retrospective cohort study 93%
- Machine learning based prediction of recurrence after curative resection for rectal cancer 93%
- Survival benefit of adjuvant therapy following neoadjuvant therapy in patients with resected esophageal cancer: a retrospective cohort study 93%
Similar papers in this journal
- Detecting PI3K and TP53 Pathway Disruptions in Early-Onset Colorectal Cancer Among Hispanic/Latino Patients 93%
- Added-value of whole exome and RNA Sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel 91%
- COVID-19 Outcomes in Patients with Cancer: Findings from the University of California Health System Database 91%
Similar papers in this journal
- Circulating tumor fraction analyses with ultra-low pass whole genome sequencing predict response to chemoradiation and recurrence in stage IV small cell carcinoma of the cervix: a longitudinal case study 93%
- Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma 93%
- Factors affecting COVID-19 outcomes in cancer patients - A first report from Guys Cancer Centre in London 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.